Why CoreWeave Stock Slipped This Week

CoreWeave (NASDAQ: CRWV) experienced significant stock volatility last week, falling 3.2%, driven by its proposed $9 billion acquisition of Core Scientific. The decline was exacerbated by investment firm ISS recommending Core Scientific shareholders reject the offer, fueling concerns of a higher bid. Despite CEO Michael Intrator's assurance against raising the bid, and subsequent call for support on original terms, investor sentiment remains mixed. Core Scientific shareholders are scheduled to vote on the deal on October 30th, with broad expectations of rejection, which some CoreWeave shareholders may view as a positive outcome given their apparent opposition to the current terms.

Analysis

CoreWeave (NASDAQ: CRWV) experienced significant stock volatility last week, declining 3.2% despite a favorable market environment where the S&P 500 and Nasdaq Composite gained 1.9% and 2.3% respectively. This underperformance was directly linked to investor uncertainty surrounding its proposed $9 billion acquisition of Core Scientific, reflecting mixed investor sentiment and a negative per-ticker sentiment of -0.4 for CRWV.

The proposed buyout faces considerable opposition, with investment firm ISS recommending Core Scientific shareholders reject the offer on October 20. This recommendation, coupled with existing mixed sentiment among CoreWeave shareholders, fueled fears of a potential increase in the bid price, leading to initial sell-offs in CRWV stock.

While CoreWeave CEO Michael Intrator subsequently assured investors the company would not hike its bid, shares fell again after he urged Core Scientific shareholders to support the original terms. The upcoming vote on October 30 is broadly expected to result in a rejection of the deal, which could paradoxically serve as a positive near-term catalyst for CRWV, aligning with the views of shareholders who deem the buyout not in the company's best interest. Despite recent fluctuations, CRWV stock remains up 231% in 2025.

Key Decisions for Investors

• Monitor the Core Scientific shareholder vote on October 30 for the $9 billion buyout decision, as its outcome is a critical near-term catalyst for CoreWeave.
• Evaluate the potential for a positive near-term catalyst for CoreWeave if the acquisition is rejected, given shareholder opposition to the deal's current terms.
• Assess CoreWeave's valuation and long-term strategy, considering the current negative sentiment surrounding its M&A activities despite strong year-to-date performance.